BioSpace News Archive

ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2022 on Thursday, October 28, 2021, after the New York Stock Exchange closes.

Mersana Therapeutics, Inc. (NASDAQ:MRSN), today announced that XMT-2056, its first Immunosynthen STING-agonist ADC candidate, targets a novel epitope of human epidermal growth factor receptor 2 (HER2) and presented new preclinical data during a plenary session at the AACR-NCI-EORTC Virtual International Conference.

Plexium, Inc., a biotech company focused on discovering and developing protein degrading therapeutics directed towards historically challenging drug targets, announced that company management will present and host one-on-one meetings at the Solebury Trout/BMO Fall Private Company Showcase 2021.

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will host a conference call and webcast for investors and analysts on Monday, October 11, 2021, at 2:30 pm ET.

Apollo Endosurgery, Inc. announced preliminary unaudited financial results and corporate updates for the third quarter ended September 30, 2021, including anticipated revenue in the range of $16.0 million to $16.4 million and anticipated revenue growth in the range of 25% to 28% compared to third quarter 2020.

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced a non-exclusive clinical collaboration agreement with Sanofi to evaluate the combination of adagrasib, the Company’s investigational KRASG12C inhibitor, with Sanofi’s investigational SHP2 inhibitor SAR442720, also known as RMC-4630.

Monte Rosa Therapeutics, Inc., a biotechnology company developing novel molecular glue-based precision medicines, announced preclinical data describing the potential of the company’s GSPT1-directed molecular glue degraders to address Myc-driven cancers.

Helsinn Group, a Swiss Biopharmaceutical Group with an innovative R&D pipeline in cancer supportive care and oncology therapeutics, strategically investing in a fully integrated targeted therapy structure to develop, manufacture and commercialize small molecules in precision medicine with higher market potential, today announces the acceptance of two abstracts on a potent and highly selective RET inhibitor at the AACR-NCI-EORTC Virtual International Conference.

ORIC Pharmaceuticals, Inc. today announced multiple presentations, including initial clinical data from an ongoing Phase 1b study evaluating ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide, in patients with metastatic prostate cancer progressing on enzalutamide.

Rakovina Therapeutics Inc. (the “Company”) (TSX-V: RKV) today announced that the Company has received notice of allowance from the Untied States Patent and Trademark Office (USPTO) for a patent entitled “Tricyclic Inhibitors of Poly(ADP-Ribose) Polymerase.”